1. Home
  2. TRDA vs PLRX Comparison

TRDA vs PLRX Comparison

Compare TRDA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRDA
  • PLRX
  • Stock Information
  • Founded
  • TRDA 2016
  • PLRX 2015
  • Country
  • TRDA United States
  • PLRX United States
  • Employees
  • TRDA N/A
  • PLRX N/A
  • Industry
  • TRDA Biotechnology: Pharmaceutical Preparations
  • PLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TRDA Health Care
  • PLRX Health Care
  • Exchange
  • TRDA Nasdaq
  • PLRX Nasdaq
  • Market Cap
  • TRDA 609.7M
  • PLRX 641.5M
  • IPO Year
  • TRDA 2021
  • PLRX 2020
  • Fundamental
  • Price
  • TRDA $17.63
  • PLRX $14.67
  • Analyst Decision
  • TRDA Strong Buy
  • PLRX Strong Buy
  • Analyst Count
  • TRDA 3
  • PLRX 7
  • Target Price
  • TRDA $21.67
  • PLRX $40.50
  • AVG Volume (30 Days)
  • TRDA 166.9K
  • PLRX 433.1K
  • Earning Date
  • TRDA 11-05-2024
  • PLRX 11-07-2024
  • Dividend Yield
  • TRDA N/A
  • PLRX N/A
  • EPS Growth
  • TRDA N/A
  • PLRX N/A
  • EPS
  • TRDA 3.04
  • PLRX N/A
  • Revenue
  • TRDA $239,397,000.00
  • PLRX N/A
  • Revenue This Year
  • TRDA $39.06
  • PLRX N/A
  • Revenue Next Year
  • TRDA N/A
  • PLRX $683.64
  • P/E Ratio
  • TRDA $5.76
  • PLRX N/A
  • Revenue Growth
  • TRDA 451.22
  • PLRX N/A
  • 52 Week Low
  • TRDA $10.75
  • PLRX $10.22
  • 52 Week High
  • TRDA $18.17
  • PLRX $19.62
  • Technical
  • Relative Strength Index (RSI)
  • TRDA 61.79
  • PLRX 69.09
  • Support Level
  • TRDA $15.65
  • PLRX $10.99
  • Resistance Level
  • TRDA $18.01
  • PLRX $15.25
  • Average True Range (ATR)
  • TRDA 0.75
  • PLRX 0.80
  • MACD
  • TRDA 0.17
  • PLRX 0.46
  • Stochastic Oscillator
  • TRDA 86.52
  • PLRX 88.47

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Share on Social Networks: